Replies to post #2628 on Lisata Therapeutics Inc (LSTA)

[akasidney86]

Note to Maddie Sorenson, author of the AnalystRatings.net report:

You wrote:

Its lead product candidate based on this platform technology is NBS20 (targeted cancer immunotherapy), which is in Phase II trials focuses on malignant melanoma as an initial indication.

Now, I like the price target of $9.67, but what do you think it would be if you knew that the trial you refer to above is a Phase 3 trial that has been granted special protocol assessment (SPA). The SPA letter states that the Phase 3 clinical trial is adequately designed to support a Biologics License Application (BLA) seeking marketing approval of CLBS20 if endpoints are met. CLBS20 has also received fast-track and Orphan Drug designation by the US FDA as well as Advanced Therapeutic Medicinal Product classification by the European Medicines Agency (EMA).... and not a Phase II trial as you foolishly state? Due to finish enrollment in 2016.

Anybody out there who knows Maddie and could clue her in?

[hbhmb]

here's hoping this year all of the " analyst" projections are
correct


a healthy , happy and prosperous new year to all the faithful
on this board.